Colon Cancer Clinical Trial

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Summary

RATIONALE: Drugs used in chemotherapy, such as ursodiol, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Giving ursodiol together with leucovorin calcium, fluorouracil, oxaliplatin, and bevacizumab may be an effective treatment for colorectal cancer.

PURPOSE: This phase I trial is studying the side effects and best dose of ursodiol when given together with combination chemotherapy and bevacizumab in treating patients with stage IV colorectal cancer.

View Full Description

Full Description

OBJECTIVES:

Primary

To determine the active dose and/or maximum tolerated dose of ursodiol when given in combination with fluorouracil, leucovorin calcium, oxaliplatin (FOLFOX regimen), and bevacizumab in patients with metastatic colorectal cancer.
To determine the pharmacokinetics of ursodiol when given with this regimen.

Secondary

To determine the systemic metabolic effects of ursodiol activation of nuclear receptor farnesoid X receptor (FXR) in glucose and lipid metabolism.
To develop assays to detect ursodiol activation of FXR.
To identify and evaluate potential serum biomarkers of FXR activation.
To determine genes regulated by activation of FXR at target tissues.

OUTLINE: This is a dose-escalation study of ursodiol.

Patients receive oral ursodiol twice daily on days 1-28 (days -6 to 28 of course 1), leucovorin calcium intravenously (IV) over 2 hours on days 1 and 15, fluorouracil IV over 46 hours on days 1-2 and 15-16, and oxaliplatin IV over 2 hours and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Blood sample is collected periodically for pharmacokinetic studies. Samples are also analyzed for the role of nuclear receptor farnesoid X receptor (FXR) in glucose uptake and metabolism using PET scan imaging, an oral glucose tolerance test, and HbA1c levels; the effects of FXR activation on lipid metabolism; and a marker for response to FXR activation via western blot. Available formalin-fixed paraffin-embedded tumor tissue blocks are analyzed for FXR expressing via IHC; expression of known FXR target genes via RNA analysis and real-time PCR; and expression of genes involved in glucose metabolism.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients with advanced, biopsy proven metastatic colorectal cancer
Karnofsky Performance Status >= 80
Prior therapy completed at least 3 weeks before protocol treatment initiation with recovery from any side-effects
Serum albumin and prealbumin within normal limits
Alanine aminotransferase (ALT) within 3 x upper limit of normal
Alkaline phosphatase within 3 x upper limit of normal
Serum bilirubin within normal limits
Absolute neutrophil count >= 1500/ul
Serum creatinine within 1.5 x upper limit of normal
Ability to understand and sign an institutional review board (IRB) approved informed consent
Ability to use appropriate contraception and no evidence of pregnancy in female patients of reproductive potential

Exclusion Criteria:

Significant medical or psychiatric condition that would make treatment unsafe
Use of systemic steroids use within 7 days from start of trial
Nursing women
Patients unable to comply with protocol related studies and follow up
Weight loss of greater than 10% in the last 6 months

Study is for people with:

Colon Cancer

Phase:

Phase 1

Estimated Enrollment:

11

Study ID:

NCT00873275

Recruitment Status:

Active, not recruiting

Sponsor:

City of Hope Medical Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

City of Hope Medical Center
Duarte California, 91010, United States

How clear is this clinincal trial information?

Study is for people with:

Colon Cancer

Phase:

Phase 1

Estimated Enrollment:

11

Study ID:

NCT00873275

Recruitment Status:

Active, not recruiting

Sponsor:


City of Hope Medical Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.